ReviewEuropean journal of haematology2022
Assessing the risk of thromboembolism in cancer patients receiving immunotherapy.
Review in European journal of haematology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Cardiovascular toxicity induced by immunotherapy in non-small cell lung cancer: a systematic review and meta-analysis of observational studies.Frontiers in oncology · 2025Pooled it
- A Phase II Study of Docetaxel and Pembrolizumab plus Interleukin 12 Gene Therapy in Nonmetastatic, Anthracycline-Refractory Triple-Negative Breast Cancer (INTEGRAL).Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- The Immune Checkpoint Inhibitors Journey: From Early Promise to Lasting Impact.Journal of immunotherapy and precision oncology · 2026Review
- Venous thromboembolism mortality trends among us adults with cancer, 1999-2024.Journal of thrombosis and thrombolysis · 2026Article
- Plasma proteomics improves thrombosis prediction in patients with cancer and identifies targetable IL-17-driven endothelial activation.Science translational medicine · 2026Article
- Cancer-Associated Arterial Thrombosis: Mechanisms and Risk Factors.Oncology research · 2026Review
- Immune checkpoint inhibitors combined with chemotherapy enhance coagulation activation and elevate venous thromboembolism risk in non-small cell lung cancer.American journal of cancer research · 2026Article
- Post marketing safety surveillance of atezolizumab based on a retrospective analysis of the FDA adverse events reporting system (FAERS).Scientific reports · 2025Article
- Thromboembolism in patients with melanoma receiving immune checkpoint inhibitors: incidence and risk factors.Immuno-oncology technology · 2025Article
- Venous Thromboembolic Events in Cancer Immunotherapy: A Narrative Review.Journal of clinical medicine · 2025Review
- Validation of risk assessment models for venous thromboembolism in patients with cancer receiving systemic therapies.Blood advances · 2025Observational
- Exploring the Emerging Association Between Immune Checkpoint Inhibitors and Thrombosis.Journal of clinical medicine · 2025Review
- Immune checkpoint inhibitor-associated risk for venous thromboembolism: a comprehensive analysis.Journal for immunotherapy of cancer · 2025Article
- Influence of the Immune Checkpoint Inhibitors on the Hemostatic Potential of Blood Plasma.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2025Article
- Venous and Arterial Thromboembolism in Lung Cancer Patients: A Retrospective Analysis.Journal of clinical medicine · 2024Article
- Article
- Tissue factor pathway-related biomarkers in liver cancer: activated factor VII-antithrombin complex and tissue factor mRNA levels are associated with mortality.Research and practice in thrombosis and haemostasis · 2024Article
- Checkpoint inhibitors.Hematology. American Society of Hematology. Education Program · 2023Article
- Article
- Incidence of venous thromboembolism and association with PD-L1 expression in advanced non-small cell lung cancer patients treated with first-line chemo-immunotherapy.Frontiers in oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
Abstract
Malignancy has long been implicated with hypercoagulability, leading to an increased rate of both venous and arterial thromboembolic events (VTE and ATE). Immunotherapy has established itself as a cornerstone of modern cancer therapy by promoting antitumor immune responses, though there have been some suggestions that immune-related adverse events could include increased rates of VTE and ATE. In this review, we examine the available evidence regarding the use of immune checkpoint inhibitors (ICIs) and thrombosis. First, we describe the potential mechanisms by which ICIs might lead to thrombophilia given the overlap between the immune system, coagulation cascade, and platelet adhesion and activation. In addition, while there are some preclinical data evaluating immunotherapy-associated ATEs in animal models, there is a paucity of evidence exploring potential mechanism of VTEs in ICIs. Second, we review the incidence of ATE and VTE in patients receiving ICIs in the published literature. Finally, we discuss current limitations in understanding, areas of conflicting evidence, and approaches to further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.